Risk of spontaneous preterm birth assessed by point-of-care testing

Qiagen has received US regulatory approval for PartoSure, a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labour. Approval by the US Food and Drug Administration (FDA) follows successful uptake of the rapid test in more than 35 countries across Europe, the Middle East, Asia and Latin America.

PartoSure represents a key milestone in the development of diagnostic tests for preterm birth. A non-invasive strip test that provides results in five minutes or less, PartoSure has been shown in several published studies to have a higher positive predictive value for preterm birth compared to current diagnostic methods, while maintaining an equally high negative predictive value. The test detects placental alpha-microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labour.

PartoSure adds to Qiagen’s comprehensive Sexual and Reproductive Health portfolio, which includes the AmniSure ROM (rupture of membranes) test; differentiated core technologies and bioinformatics solutions for non-invasive prenatal testing (NIPT); and the digene HC2 HPV test to screen for human papillomavirus (HPV).

www.qiagen.com

 

Other news

Upcoming Events

Advanced Cell Culture: A Practical Approach

Coin Street Conference Centre, 108 Stamford Street, Lambeth, London SE1 9NH
8 June 2018

IBMS Annual General Meeting

Stormont Hotel, Belfast BT4 3LP
9 Jun 2018

Pathology Horizons 2018 Conference

Lough Erne Resort, Co. Fermanagh, Northern Ireland
September 13-15

Microbe 2018

Hilton Hotel, Sheffield
21-23 September 2018

World Congress of the International Federation of Biomedical Laboratory Science (IFBLS)

Palazza dei Congressi of Firenze
22-26 September 2018

Latest Issue

Pathology In Practice

Pathology In Practice

Apr 2018

A revolution in tissue block archiving and storage

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.